Abstracts

IDENTIFICATION OF SYNERGISTIC COMBINATIONS OF HIV SILENCING PROMOTING FACTORS

The activity of latent HIV is counter-regulated by both silencing and activating factors. To durably silence latent HIV (‘block-and-lock’), we will specifically define how to enhance the activity of synergistic repressors while neutralizing HIV activators in relevant host cells. In this research, we are systematically evaluating the combinations of recently identified silencing promoting factors (SPFs)…

POTENT TARGETED ACTIVATOR OF CELL KILL (TACK) MOLECULES ELIMINATE HIV-INFECTED CELLS

Strategies to address both latent and virus expressing cells that contribute to viral recrudescence upon ART cessation are required to achieve functional cure in people living with HIV-1 (PLWH). Some non-nucleoside reverse transcriptase inhibitors (NNRTIs) have a weak secondary activity that results in selective cytotoxicity by promoting dimerization of HIV-1 Gag-Pol and intracellular activation of…

GENOME-WIDE CRISPR INHIBITION SCREEN IDENTIFIES A NEW HIV-1 SILENCING FACTOR SLTM

HIV-1 persistence in latent reservoirs remains a major obstacle to cure. We postulate that HIV-1 silencing factors suppress HIV-1 reactivation, and inhibition of HIV-1 silencing factors will increase HIV-1 reactivation and guide drug designs. We conducted a genome-wide CRISPR-inhibition (CRISPRi) screen on four Jurkat T cell clones having stably integrated HIV-1-GFP reporter with known integration…

DASATINIB PREVENTS HIV INFECTION OF MACROPHAGES AND REDUCE THE INFLAMMATORY POTENTIAL

Monocyte-derived macrophages (MDMs) contribute to long-lived HIV-1 reservoirs. MDMs also release soluble factors that contribute to the chronic inflammation in HIV+ individuals. Our group previously demonstrated that tyrosine kinase inhibitor (TKI) dasatinib, but not imatinib, prevents HIV-1 infection of CD4+ T lymphocytes. In this proof-of-concept study, we analyzed whether dasatinib or imatinib also protect MDMs…

LONG-READ SEQUENCING ASSAY ALLOWS ACCURATE CHARACTERIZATION OF THE HIV-1 RESERVOIR

The advent of near full-length (NFL) HIV-1 proviral genome sequencing greatly expanded our understanding of the quality of the viral reservoir, revealing that only 2-5% of the persistent proviruses in ART-treated individuals can be considered genome-intact. However, current NFL assays are based on labor-intensive and costly principles of repeated PCRs at limiting dilution, restricting their…

HIV LATENCY REVERSAL VIA IAP ANTAGONISM AND TARGETED BET BROMODOMAIN INHIBITION

Accelerating reservoir decay through reversal of HIV latency and clearance of infected cells may facilitate an HIV cure. Recent preclinical studies have demonstrated that non-canonical NF-?B agonists (IAP antagonists, IAPi) induce unprecedented levels of proviral expression without toxicity during suppressive ART in two animal models of latent SIV/HIV infection. However, combination approaches may be needed…